(Q57759564)

Jan Delabie

3

0 references

Knut Liestøl

8

Knut Liestøl

0 references

Signe Spetalen

5

Signe Spetalen

0 references

Erlend B. Smeland

9

Erlend B Smeland

0 references

Harald Holte

10

Harald Holte

0 references

Idun Fiskvik

1

Idun Fiskvik

0 references

Klaus Beiske

2

Klaus Beiske

0 references

author name string

Olav Yri

4

0 references

Marja-Liisa Karjalainen-Lindsberg

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

6

0 references

publication date

19 November 2014

0 references

published in

Leukemia & Lymphoma

0 references

volume

56

0 references

issue

6

0 references

page(s)

1742-1749

0 references

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Targeting apoptosis pathways for new cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970550